

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

(₹ in Crores, except earning per share)

Sr. No	Particulars	Quarter ended			Year ended	
		March 31, 2022 (Audited)	December 31, 2021 (Unaudited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)
1	Income					
	Revenue from operations	103.71	79.62	105.29	341.90	333.04
	Other income	5.67	3.63	5.73	19.20	24.16
	Total income	109.38	83.25	111.02	361.10	357.20
2	Expenses					
	Cost of raw materials consumed	0.37	0.28	0.36	1.01	1.03
	Purchase of software products	5.27	2.62	4.04	13.00	8.33
	Changes in inventories of software products	(1.22)	(0.19)	(0.40)	(1.85)	2.28
	Employee benefits expense	39.39	33.36	31.51	139.49	114.74
	Depreciation and amortisation expense	4.58	4.54	5.00	17.38	19.49
	Other expenses	25.03	23.08	16.01	83.39	65.20
	Total expenses	73.42	63.69	56.52	252.42	211.07
3	Profit before tax (1-2)	35.96	19.56	54.50	108.68	146.13
4	Tax expense					
	Current tax					
	Pertaining to profit for the current period	8.11	5.18	11.10	25.88	34.04
	Adjustments of tax relating to earlier periods	(0.00)	0.65	1.76	0.65	1.76
	Deferred tax (benefit) / charge	(0.25)	(0.55)	1.93	(1.04)	3.36
	Total tax expense	7.87	5.28	14.79	25.49	39.16
5	Profit for the period (3-4)	28.09	14.28	39.71	83.19	106.97
6	Other comprehensive income, net of tax					
	Re-measurement of defined benefit plans	0.39	0.09	0.41	0.62	0.13
	Net (loss) or gain on FVTOCI assets	2.08	-	-	2.08	-
	Exchange differences on translation of foreign operations	(0.08)	(0.10)	(0.07)	(0.25)	(0.36)
	Total other comprehensive income	2.39	(0.01)	0.34	2.45	(0.23)
7	Total comprehensive income (after tax) (5+6)	30.48	14.27	40.06	85.64	106.74
8	Paid-up equity share capital (face value of ₹10 each)	58.01	57.96	64.21	58.01	64.21
9	Other equity				569.62	687.27
10	Earnings per share of ₹10 each: (not annualised for the quarter)					
	a) Basic	4.85	2.47	6.19	14.01	16.66
	b) Diluted	4.82	2.45	6.18	13.94	16.65



NOTES TO THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

Notes to financial results:

- 1 The above financial results for the year ended March 31, 2022 have been subjected to Statutory Audit by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on May 05, 2022. Figures for the quarter ended March 31, 2022 and March 31, 2021 are the balancing figures between the audited figures in respect of the full years and published year to date figures of nine month ended December 31, 2021 and December 31, 2020 respectively.
- 2 During the year ended March 31, 2019, The Parent Company had received notice of demand dated March 13, 2019, in relation to service tax under the provisions of Finance Act, 1994 for ₹38.74 (excluding interest and penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-virus software in Compact Disk. The Parent Company replied to the notice of demand to Commissioner of Goods and Service Tax, Pune.

During the earlier years, The Parent Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹122.31 (excluding penalty of ₹62.70 and pre-deposit, if any) covering the period from March 1, 2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2011 to March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April 1, 2014 to March 31, 2016.

The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 of 2016), has set aside the Service Tax demand for ₹56.07 along with interest and penalty which was earlier confirmed by Directorate General of Central Excise Intelligence (DGCEI), New Delhi vide its Order of 2016 covering period from March 1, 2011 to March 31, 2014.

Based on this latest judgement of CESTAT, New Delhi, technical circular issued by government authorities and an independent legal opinion obtained by the Parent Company in earlier years, the Company is confident to get relief and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, no provision/contingent liability has been recognized/disclosed in the financial statements.

The Commissioner of Service Tax, Delhi has preferred an appeal against the above said Order passed by the Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT) amounting to ₹56.07 and hearing for admission level is pending with the Hon'ble Supreme Court.
- 3 The Board of Directors of the Holding Company at its meeting held on March 10, 2021 and the shareholders by way of postal ballot on April 18, 2021, approved the buy back of the Holding Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Holding Company including promoters of the Company as on the record date, on a proportionate basis through the "tender offer" route at a price of ₹245 per share for an aggregate amount not exceeding ₹155. The Company completed the Buy Back Process on June 24, 2021 and has complied with all the requisite formalities with SEBI and ROC.


In line with the requirement of the Companies Act, 2013, an amount of ₹59.43 and ₹125.27 (Including tax on buy back of ₹36.03) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of ₹6.32 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹6.32. Further, transaction cost of buy back of shares of ₹1.72 has been reduced from retained earnings.
- 4 The Board of Directors have recommended the dividend of ₹4.5 per equity share of the face value of ₹10.00 per share for the year ended March 31, 2022. The payment of dividend is subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.
- 5 The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 6 **Estimated uncertainty relating to COVID-19 outbreak**
The World Health Organization announced a global health emergency because of a new strain of coronavirus ("COVID-19") and classified its outbreak as a pandemic on March 11, 2020. In response, the Indian government have taken various actions and ensured many precautionary measures which posed significant disruption to business operations and adversely impacting most of the industries which has resulted in global slowdown.

The full extent and duration of the impact of COVID-19 on the Company's operations and financial performance is currently unknown, and depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic and any new information that may emerge concerning the severity of the virus, its spread to other regions and the actions to contain the virus or treat its impact, among others.

Any of these outcomes could have a material adverse impact on Company's business, financial condition, results of operations and cash flows for the year ended March 31, 2021 and thereafter.

Management currently believes that it has adequate liquidity and business plans to continue to operate the business and mitigate the risks associated with COVID-19 for the next 12 months from the date of these Financial Statements.
- 7 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
Date: May 05, 2022



For and on behalf of the Board of Directors

Kailash Katkar
Managing Director
& Chief Executive Officer

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT MARCH 31, 2022

(₹ in crores, except per share data)

	As at March 31, 2022 (Audited)	As at March 31, 2021 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	105.94	140.47
(b) Capital work-in-progress	-	2.11
(c) Intangible assets	5.74	5.28
(d) Investment Property	25.36	-
(e) Financial assets		
(i) Investments	27.46	32.19
(ii) Other financial assets	0.49	0.54
(f) Income tax assets (net)	15.80	12.15
(g) Other non-current assets	0.47	2.46
	181.25	195.20
Current assets		
(a) Inventories	4.79	3.34
(b) Financial assets		
(i) Investments	290.07	383.31
(ii) Trade receivables	171.96	150.63
(iii) Cash and cash equivalents	7.83	16.43
(iv) Bank balances other than (iii) above	55.22	67.89
(v) Other financial assets	1.17	1.48
(c) Other current assets	3.58	6.81
(d) Assets classified as held for sale	-	1.60
	534.62	631.49
Total assets	715.88	826.69
Equity and liabilities		
Equity		
(a) Equity share capital	58.01	64.21
(b) Share application money pending allotment	-	-
(c) Other equity	569.62	687.27
Total equity	627.63	751.48
Liabilities		
Non-current liabilities		
(a) Net employee defined benefit liabilities	0.89	0.37
(b) Other non-current liabilities	0.52	-
(c) Deferred tax liability (net)	0.64	0.82
	2.05	1.19
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	5.77	1.33
(b) Total outstanding dues creditors other than micro enterprises and enterprises	59.48	48.65
(ii) Other financial liabilities	1.13	1.33
(b) Other current liabilities	19.31	18.31
(c) Net employee defined benefit liabilities	0.39	1.17
(d) Income tax liabilities (net)	0.11	3.23
	86.19	74.02
Total liabilities	88.24	75.20
Total equity and liabilities	715.88	826.69



QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

CONSOLIDATED STATEMENT OF CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022

	Period ended	
	March 31, 2022 (Audited)	March 31, 2021 (Audited)
A. Cash flow from operating activities		
Profit before tax	108.68	146.13
Adjustment to reconcile profit before tax to net cash flows:		
Exceptional items		
Net (gain) / loss foreign exchange differences	(0.23)	(0.35)
Employee share based payments expense	4.69	0.62
Depreciation and amortization expense	17.38	19.49
Interest income	(2.90)	(7.13)
Provision for doubtful debts and advances	3.36	(3.81)
Bad debts written off	0.08	3.48
Property, plant and equipment written off	0.09	-
(Profit) / Loss on sale of property, plant and equipment	(1.65)	(0.04)
Exchange difference on translation of foreign currency cash and cash equivalents	0.08	0.07
Net (gain) on sale of investment	(2.84)	(3.01)
Net (gain) / loss on FVTPL current investment	(7.41)	(9.00)
Operating profit before working capital changes	119.33	146.45
Movements in working capital:		
(Increase)/decrease in trade receivables	(24.86)	(37.14)
(Increase)/decrease in inventories	(1.45)	2.91
(Increase)/decrease in other financial assets	0.71	0.09
(Increase)/decrease in other assets	3.05	(2.16)
Increase/(decrease) in net employee defined benefit liabilities	0.57	0.85
Increase/(decrease) in trade payables	15.26	9.24
Increase/(decrease) in other current liabilities	1.52	7.68
Cash generated from operations	114.13	127.92
Direct taxes paid (net of refunds)	(33.30)	(29.30)
Net cash flow from operating activities (A)	80.83	98.62
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(5.85)	(8.86)
Proceeds from sale of property, plant and equipment	4.49	0.04
Purchase of current investments	(408.85)	(621.89)
Sale of current investments	519.80	528.26
(Increase)/decrease in bank balances other than cash and cash equivalents	12.70	2.31
Interest received	2.52	7.86
Net cash (used in) investing activities (B)	124.81	(92.29)
C. Cash flow from financing activities		
Dividend paid on equity shares	(23.15)	0.05
Tax on Buyback	(36.03)	-
Proceeds from issuance of equity shares (including securities premium and Buy back)	1.74	0.05
Buyback Expenses	(1.72)	-
Payout on Buyback of equity shares	(155.00)	-
Share application money pending allotment	-	-
Net cash flow (used in) financing activities (C)	(214.16)	0.10
Net (decrease) in cash and cash equivalents (A+B+C)	(8.52)	6.43
Cash and cash equivalents at the beginning of the year	16.43	10.07
Effect of exchange differences on cash and cash equivalents held in foreign currency	(0.08)	(0.07)
Cash and cash equivalents at the end of the year	7.83	16.43
Components of cash and cash equivalents		
Cash on hand	0.06	0.06
Balances with banks		
On current account	7.14	13.16
On EEFC account	0.63	3.14
Cheques on hand	-	0.07
Total cash and cash equivalents	7.83	16.43



QUICK HEAL TECHNOLOGIES LIMITED
 Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
 CIN: L72200MH1995PLC091408

STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

(₹ in crores, except per share data)

Sr. No	Particulars	Quarter ended			Year ended	
		March 31, 2022 (Audited)	December 31, 2021 (Unaudited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)
1	Income					
	Revenue from operations	103.75	79.63	106.11	341.55	333.53
	Other income	5.66	3.63	5.72	19.17	23.94
	Total income	109.41	83.26	111.83	360.72	357.47
2	Expenses					
	Cost of raw materials consumed	0.36	0.28	0.36	1.00	1.03
	Purchase of security software products	5.25	2.62	4.04	13.30	8.05
	Increase / (decrease) in inventories of security software products	(1.22)	(0.20)	(0.39)	(1.89)	2.30
	Employee benefits expense	39.08	33.07	31.14	138.34	113.20
	Depreciation and amortisation expense	4.58	4.54	5.00	17.38	19.48
	Other expenses	25.59	23.40	16.89	84.97	67.59
	Total expenses	73.64	63.71	57.04	253.10	211.65
3	Profit before exceptional items and tax (1-2)	35.77	19.55	54.79	107.62	145.82
4	Exceptional items (refer note 3)	1.90	-	-	4.06	-
5	Profit before tax (3-4)	33.87	19.55	54.79	103.56	145.82
6	Tax expense					
	Current tax					
	Pertaining to profit for the current period	8.07	5.15	11.08	25.76	33.92
	Adjustments of tax relating to earlier periods (Net)	-	0.65	1.76	0.65	1.76
	Deferred tax (benefit/ charge)	(0.23)	(0.55)	1.93	(1.04)	3.36
	Total tax expense	7.84	5.25	14.77	25.37	39.04
7	Profit for the period (5-6)	26.03	14.30	40.02	78.19	106.78
8	Other comprehensive income, net of tax					
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:					
	Re-measurement of defined benefit plans	0.39	0.09	0.41	0.62	0.13
	Net (loss) or gain on FVTOCI assets	2.08	-	-	2.08	-
	Total other comprehensive income	2.47	0.09	0.41	2.70	0.13
9	Total comprehensive income (after tax) (7+8)	28.50	14.39	40.43	80.89	106.91
10	Paid-up equity share capital (face value of ₹ 10 each)	58.01	57.96	64.21	58.01	64.21
11	Other equity (as per balance sheet of previous accounting year)	-	-	-	569.20	691.59
12	Earnings per share of ₹ 10 each: (not annualised except for the year ended March)					
	a) Basic	4.49	2.47	6.24	13.17	16.64
	b) Diluted	4.47	2.45	6.22	13.10	16.62



QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

Notes to financial results:

- 1 The above financial results for the year ended March 31, 2022 have been subjected to statutory audit by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on May 05, 2022. Figures for the quarter ended March 31, 2022 and March 31, 2021 are the balancing figures between the audited figures in respect of the full years and published year to date figures of nine month ended December 31, 2021 and December 31, 2020 respectively.
- 2 During the year ended March 31, 2019, Company had received notice of demand dated March 13, 2019, in relation to service tax under the provisions of Finance Act, 1994 for ₹ 38.74 (excluding interest and penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-virus software in Compact Disk. Company replied to the notice of demand to Commissioner of Goods and Service Tax, Pune.
- During the earlier years, Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹ 122.31 (excluding penalty and pre-deposit, if any) covering the period from March 1, 2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2011 to March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April 1, 2014 to March 31, 2016.
- The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 of 2016), has set aside the Service Tax demand for ₹ 56.07 along with interest and penalty which was earlier confirmed by Directorate General of Central Excise Intelligence (DGCEI), New Delhi vide its Order of 2016 covering period from for the period March 1, 2011 to March 31, 2014.
- Based on this latest judgement of CESTAT, New Delhi, technical circular issued by government authorities and an independent legal opinion obtained by the Company in earlier years, the Company is confident to get relief and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, no provision/contingent liability has been recognized/disclosed in the financial statements.
- The Commissioner of Service Tax, Delhi has preferred an appeal against the above said Order passed by the Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT) amounting to ₹56.07 and hearing for admission level is pending with the Hon'ble Supreme Court.

3 **Impairment of investments**
Included in exceptional items

(₹ in crores)


Particulars	Standalone				
	Quarter ended		Year ended		
	March 31, 2022 (Audited)	December 31, 2021 (Unaudited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)
Impairment of investment in wholly owned subsidiaries	1.90	-	-	4.06	-

- 4 The Board of Directors of the Company at its meeting held on March 10, 2021 and the shareholders by way of postal ballot on April 18, 2021, approved the buy back of the Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Company including promoters of the Company as on the record date, on a proportionate basis through the "tender offer" route at a price of ₹245 per share for an aggregate amount not exceeding ₹155.0. The Company completed the Buy Back Process on June 24, 2021 and has complied with all the requisite formalities with SEBI and ROC.
- In line with the requirement of the Companies Act, 2013, an amount of ₹59.43 and ₹125.27 (Including tax on buy back of ₹36.03) has been utilised from securities premium and retained earnings respectively. In accordance with section 69 of the Companies Act, 2013, capital redemption reserve of ₹6.33 (representing the nominal value of the shares bought back) has been created as an apportionment from retained earnings. Consequent to such buy back, the paid-up equity share capital has reduced by ₹6.33. Further, transaction cost of buy back of shares of ₹1.72 has been reduced from retained earnings.
- 5 The Board of Directors have recommended the dividend of ₹4.5 per equity share of the face value of ₹10.00 per share for the year ended March 31, 2022. The payment of dividend is subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.



- 6 The Company is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 7 **Estimated uncertainty relating to COVID-19 outbreak**
The World Health Organization announced a global health emergency because of a new strain of coronavirus ("COVID-19") and classified its outbreak as a pandemic on March 11, 2020. In response, the Indian government have taken various actions and ensured many precautionary measures which posed significant disruption to business operations and adversely impacting most of the industries which has resulted in global slowdown.
- The full extent and duration of the impact of COVID-19 on the Company's operations and financial performance is currently unknown, and depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic and any new information that may emerge concerning the severity of the virus, its spread to other regions and the actions to contain the virus or treat its impact, among others.
- Any of these outcomes could have a material adverse impact on Company's business, financial condition, results of operations and cash flows for the year ended March 31, 2021 and thereafter.
- Management currently believes that it has adequate liquidity and business plans to continue to operate the business and mitigate the risks associated with COVID-19 for the next 12 months from the date of these Financial Statements.
- 8 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
Date: May 05, 2022



For and on behalf of the Board of Directors

A handwritten signature in blue ink, appearing to read "K Katkar".

Kailash Katkar
Managing Director
& Chief Executive Officer

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
CIN: L72200MH1995PLC091408

STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT MARCH 31, 2022

(₹ in crores, except per share data)

	As at March 31, 2022 (Audited)	As at March 31, 2021 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	105.94	140.45
(b) Capital work-in-progress	-	2.11
(c) Intangible assets	5.72	5.26
(d) Investment Property	25.36	-
(e) Investments in subsidiaries	2.98	12.23
(f) Financial assets		
(i) Investments	27.47	32.19
(ii) Other financial assets	0.49	0.54
(g) Income tax assets (net)	15.79	12.15
(h) Other non-current assets	0.47	2.46
	184.22	207.39
Current assets		
(a) Inventories	4.79	3.29
(b) Financial assets		
(i) Investments	290.07	383.31
(ii) Trade receivables	172.93	149.44
(iii) Cash and cash equivalents	3.97	9.50
(iv) Bank balances other than (iii) above	55.23	67.89
(v) Other financial assets	1.18	1.45
(c) Other current assets	3.50	6.68
(d) Assets classified as held for sale	-	1.60
	531.67	623.16
Total assets	715.89	830.55
Equity and liabilities		
Equity		
(a) Equity share capital	58.01	64.21
(b) Share application money pending allotment	-	-
(c) Other equity	569.20	691.59
Total equity	627.21	755.80
Liabilities		
Non-current liabilities		
(a) Net employee defined benefit liabilities	0.89	0.37
(b) Other non-current liabilities	0.52	-
(c) Deferred tax liabilities (net)	0.64	0.82
	2.05	1.19
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	5.77	1.33
(b) Total outstanding dues creditors other than micro enterprises and enterprises	59.97	48.35
(ii) Other financial liabilities	1.14	1.33
(b) Other current liabilities	19.29	18.22
(c) Net employee defined benefit liabilities	0.39	1.16
(d) Income tax liabilities (net)	0.07	3.17
	86.63	73.56
Total liabilities	88.68	74.75
Total equity and liabilities	715.89	830.55



Quick Heal Technologies Limited

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STANDALONE STATEMENT OF CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022

	March 31, 2022	March 31, 2021
A. Cash flow from operating activities		
Profit before tax	103.56	145.82
Adjustment to reconcile profit before tax to net cash flows:		
Exceptional items	4.06	-
Net (gain) / loss foreign exchange differences	0.09	0.29
Employee share based payments expense	4.69	0.62
Depreciation and amortization expense	17.38	19.48
Interest income	(2.90)	(7.13)
Provision for doubtful debts and advances	3.36	(3.86)
Property, plant and equipment written off	0.08	-
Bad debts written off	0.06	3.47
(Profit) / loss on sale of property, plant and equipment	(1.66)	(0.04)
Net gain on sale of investment	(2.84)	(3.01)
Net (gain) on FVTPL current investment	(7.41)	(9.00)
Operating profit before working capital changes	118.47	146.64
Movements in working capital:		
(Increase)/decrease in trade receivables	(27.00)	(36.11)
(Increase)/decrease in inventories	(1.50)	2.93
(Increase)/decrease in other financial assets	0.20	0.05
(Increase)/decrease in other assets	3.00	(1.78)
Increase/(decrease) in net employee defined benefit liabilities	0.58	0.84
Increase/(decrease) in trade payables	16.06	9.01
Increase/(decrease) in other current & non-current liabilities	1.59	7.88
Cash generated from operations	111.40	129.46
Direct taxes paid (net of refunds)	(32.34)	(29.17)
Net cash flow from operating activities (A)	79.06	100.29
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(5.75)	(8.87)
Proceeds from sale of property, plant and equipment	4.30	0.06
Repatriation of funds / (Investments in subsidiaries)	5.19	(2.17)
Purchase of current investments	(408.85)	(621.89)
Sale of current investments	519.14	528.25
(Increase)/decrease in bank balances other than cash and cash equivalents	12.69	2.29
Interest received	2.83	7.87
Net cash (used in) investing activities (B)	129.55	(94.46)
C. Cash flow from financing activities		
Dividend paid on equity shares	(23.13)	0.05
Tax on Buyback	(36.03)	-
Buyback Expenses	(1.72)	-
Proceeds from issuance of equity shares (including securities premium)	1.74	0.06
Payout for buyback of shares	(155.00)	-
Share application money pending allotment	-	-
Net cash flow (used in) financing activities (C)	(214.14)	0.11
Net (decrease) in cash and cash equivalents (A+B+C)	(5.53)	5.94
Cash and cash equivalents at the beginning of the year	9.50	3.56
Cash and cash equivalents at the end of the year	3.97	9.50
Components of cash and cash equivalents		
Cash on hand	0.04	0.04
Balances with banks		
On current account	3.30	6.26
On EEFC account	0.63	3.13
Cheques on hand	-	0.07
Total cash and cash equivalents	3.97	9.50

